(VIANEWS) - Harmony Biosciences Holdings (HRMY), New York Mortgage Trust (NYMT), Toll Brothers (TOL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Harmony Biosciences Holdings (HRMY)
100.7% sales growth and 29.38% return on equity
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders.
Harmony Biosciences Holdings's sales growth this year is expected to be 88.4% and 75.3% for next year.
Year-on-year quarterly revenue growth grew by 200.8%, now sitting on 199.58M for the twelve trailing months.
Volume
Today's last reported volume for Harmony Biosciences Holdings is 162503 which is 40.83% below its average volume of 274651.
Harmony Biosciences Holdings's sales growth is a negative 0% for the current quarter and 100.7% for the next. The company's growth estimates for the present quarter and the next is a negative 0% and 314.3%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.38%.
Volatility
Harmony Biosciences Holdings's last day, last week, and last month's current volatility was 4.05%, 3.56%, and 2.60%, respectively.
Harmony Biosciences Holdings's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 5.66% (day), 6.30% (last week), and 5.12% (last month), respectively.
Harmony Biosciences Holdings's Stock Yearly Top and Bottom Value
Harmony Biosciences Holdings's stock is valued at $25.68 at 16:22 EST, way below its 52-week high of $52.74 and higher than its 52-week low of $25.10.
Harmony Biosciences Holdings's Moving Average
Harmony Biosciences Holdings's value is way under its 50-day moving average of $30.02 and way below its 200-day moving average of $31.92.2. New York Mortgage Trust (NYMT)
87.4% sales growth and 16.27% return on equity
New York Mortgage Trust, Inc. acquires, invests in, finances, and manages mortgage-related single-family and multi-family residential assets in the United States.
New York Mortgage Trust's sales growth this year is anticipated to be 34% and 13.9% for next year.
Year-on-year quarterly revenue growth declined by 0%, now sitting on 414.04M for the twelve trailing months.
Volume
Today's last reported volume for New York Mortgage Trust is 2880240 which is 9.81% below its average volume of 3193680.
New York Mortgage Trust's sales growth for the next quarter is 87.4%. The company's growth estimates for the current quarter and the next is a negative 60.7% and negative -47.8%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 16.27%.
Volatility
New York Mortgage Trust's last day, last week, and last month's current volatility was 0.69%, 1.70%, and 1.42%, respectively.
New York Mortgage Trust's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.85% (day), 3.21% (last week), and 2.68% (last month), respectively.
New York Mortgage Trust's Stock Yearly Top and Bottom Value
New York Mortgage Trust's stock is valued at $4.41 at 16:22 EST, way below its 52-week high of $4.93 and way higher than its 52-week low of $2.40.
New York Mortgage Trust's Moving Average
New York Mortgage Trust's worth is under its 50-day moving average of $4.53 and higher than its 200-day moving average of $4.36.3. Toll Brothers (TOL)
20.5% sales growth and 11.25% return on equity
Toll Brothers, Inc., together with its subsidiaries, designs, builds, markets, sells, and arranges finance for detached and attached homes in luxury residential communities in the United States.
Toll Brothers's sales growth this year is anticipated to be 23% and 21.5% for next year.
Year-on-year quarterly revenue growth grew by 24.6%, now sitting on 7.69B for the twelve trailing months.
Volume
Today's last reported volume for Toll Brothers is 727364 which is 49.73% below its average volume of 1447000.
Toll Brothers's sales growth is a negative 0% for the ongoing quarter and 20.5% for the next. The company's growth estimates for the present quarter and the next is 72.2% and 58.7%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.25%.
Volatility
Toll Brothers's last day, last week, and last month's current volatility was 0.18%, 1.85%, and 1.28%, respectively.
Toll Brothers's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.42% (day), 2.78% (last week), and 2.59% (last month), respectively.
Toll Brothers's Stock Yearly Top and Bottom Value
Toll Brothers's stock is valued at $56.46 at 16:22 EST, way below its 52-week high of $68.88 and way higher than its 52-week low of $37.25.
Toll Brothers's Moving Average
Toll Brothers's worth is under its 50-day moving average of $57.16 and under its 200-day moving average of $57.01.4. GlaxoSmithKline (GSK)
9.3% sales growth and 29.04% return on equity
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally.
GlaxoSmithKline's sales growth this year is anticipated to be 5.4% and 5.7% for next year.
Year-on-year quarterly revenue growth declined by 18.4%, now sitting on 32.43B for the twelve trailing months.
Volume
Today's last reported volume for GlaxoSmithKline is 4142140 which is 2.35% below its average volume of 4241720.
GlaxoSmithKline's sales growth is a negative 0% for the ongoing quarter and 9.3% for the next. The company's growth estimates for the ongoing quarter and the next is 28.3% and negative -10%. The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 29.04%.
Volatility
GlaxoSmithKline's last day, last week, and last month's current volatility was 1.28%, 0.81%, and 0.69%, respectively.
GlaxoSmithKline's current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 1.46% (day), 0.82% (last week), and 0.90% (last month), respectively.
GlaxoSmithKline's Stock Yearly Top and Bottom Value
GlaxoSmithKline's stock is valued at $39.52 at 16:22 EST, under its 52-week high of $42.40 and way higher than its 52-week low of $33.26.
GlaxoSmithKline's Moving Average
GlaxoSmithKline's worth is under its 50-day moving average of $39.85 and higher than its 200-day moving average of $37.68.Previous days news about GlaxoSmithKline(GSK)
According to The Wall Street Journal on Friday, 23 July, "Sanofi SA, GlaxoSmithKline PLC and Pfizer Inc. are all working on mRNA shots against seasonal flu, betting the technology will be more effective, and quicker and cheaper to make than traditional shots. "
According to Bloomberg Quint on Friday, 23 July, "While elevated material cost remains a near-term worry - a potential revival in EPS growth momentum after a relative lull in recent quarters, continued synergies from GlaxoSmithKline (tracking ahead of expectations so far), HUL pulling further ahead of peers in terms of technology and analytics and strong track record in recent"
According to Bloomberg Quint on Friday, 23 July, "Including GlaxoSmithKline Consumer Healthcare Ltd., revenue/ Ebitda/adjusted profit after tax grew 12.8%/7.7%/4.4% YoY."